This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Marco Pahor, MD; Ronald I. Shorr, MD; Grant W. Somes, PhD; William C. Cushman, MD; Luigi Ferrucci, MD; James E. Bailey, MD, MPH; Janet T. Elam, BS; William B. Applegate, MD

Arch Intern Med. 1998;158:1340-1345.

Background  It is expected that the treatment of hypertension in patients with renal disease decreases the risk of cardiovascular events, but the evidence in these patients is lacking.

Objective  To assess the effect of diuretic-based treatment on cardiovascular events in patients with isolated systolic hypertension and renal dysfunction.

Methods  A total of 4336 persons aged 60 years and older with systolic blood pressures of 160 mm Hg and higher and diastolic blood pressures of less than 90 mm Hg were randomly assigned to receive either placebo or chlorthalidone (12.5-25.0 mg/d), with the addition of atenolol (25-50 mg/d) or reserpine (0.05-0.10 mg/d) if needed, and observed for 5 years. The risk of first-occurring cardiovascular events, including stroke, transient ischemic attack, myocardial infarction, heart failure, coronary artery bypass surgery, angioplasty, aneurysm, endarterectomy, sudden death, or rapid death, was stratified according to baseline serum creatinine levels (35.4-84.0, 84.1-101.6, 101.7-119.3, and 119.4-212.2 µmol/L [0.4-0.9, 1.0-1.1, 1.2-1.3, and 1.4-2.4 mg/dL]).

Results  Systolic blood pressure reduction was not affected by baseline serum creatinine levels. Active treatment did not affect the risk of serum creatinine levels becoming elevated during follow-up. The risk of hypokalemia with active treatment decreased significantly with increasing baseline serum creatinine levels. In the 4 baseline serum creatinine groups, the relative risk (95% confidence interval) of cardiovascular events developing with active treatment was 0.73 (0.54-0.97), 0.63 (0.49-0.82), 0.62 (0.44-0.87), and 0.59 (0.38-0.91). The results were similar for the outcomes of stroke or coronary artery events and in analyses stratified by sex or age.

Conclusion  Diuretic-based treatment of patients with isolated systolic hypertension prevents the development of cardiovascular events in older persons with mild renal dysfunction.

From the Department of Preventive Medicine, University of Tennessee, College of Medicine, Memphis (Drs Pahor, Shorr, Somes, Cushman, Bailey, and Applegate and Ms Elam), and the Geriatric Department, I Fraticini, Istituto Nazionale di Ricerca e Cura per gli Anziani, Florence, Italy (Dr Ferrucci). Dr Cushman has received an honorarium for giving Grand Rounds sponsored by Monarch Pharmaceuticals Inc, Bristol, Tenn, who make a brand of chlorthalidone different from that used in this study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Is early chronic kidney disease an important risk factor for cardiovascular disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease
Daly
Nephrol Dial Transplant 2007;22:ix19-ix25.
FULL TEXT  

The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
Fox et al.
J Am Coll Cardiol 2007;49:2249-2255.
ABSTRACT | FULL TEXT  

Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
Parikh et al.
Arch Intern Med 2006;166:1884-1891.
ABSTRACT | FULL TEXT  

Chronic Kidney Disease and Mortality Risk: A Systematic Review
Tonelli et al.
J. Am. Soc. Nephrol. 2006;17:2034-2047.
ABSTRACT | FULL TEXT  

Chronic kidney disease as cause of cardiovascular morbidity and mortality
Vanholder et al.
Nephrol Dial Transplant 2005;20:1048-1056.
ABSTRACT | FULL TEXT  

Clinical Significance of Renal Function in Hypertensive Patients at High Risk: Results From the INSIGHT Trial
de Leeuw et al.
Arch Intern Med 2004;164:2459-2464.
ABSTRACT | FULL TEXT  

Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE)
Santopinto et al.
Heart 2003;89:1003-1008.
ABSTRACT | FULL TEXT  

Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
Freeman et al.
J Am Coll Cardiol 2003;41:718-724.
ABSTRACT | FULL TEXT  

Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension: Results from the Syst-Eur Trial
de Leeuw et al.
J. Am. Soc. Nephrol. 2002;13:2213-2222.
ABSTRACT | FULL TEXT  

Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency
Tonelli et al.
Nephrol Dial Transplant 2002;17:1426-1433.
ABSTRACT | FULL TEXT  

The prognostic importance of creatinine clearance after acute myocardial infarction
Sorensen et al.
Eur Heart J 2002;23:948-952.
ABSTRACT | FULL TEXT  

Slowing the progression of chronic renal insufficiency
Tonelli et al.
CMAJ 2002;166:906-907.
FULL TEXT  

Risks associated with renal dysfunction in patients in the coronary care unit
McCullough et al.
J Am Coll Cardiol 2000;36:679-684.
ABSTRACT | FULL TEXT  

Advances in the Treatment of Hypertension
Pickering
JAMA 1999;281:114-116.
FULL TEXT